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Abstract
Background a2-Adrenoceptor agonists are used adjunc-
tively to psychostimulants in treating attention-deficit/
hyperactivity disorder (ADHD) when psychostimulants
alone do not sufficiently reduce symptoms. However, data
on the pharmacokinetic profiles and safety of combination
treatments in ADHD are needed.
Objective The primary objective of this study was to
evaluate the pharmacokinetic profiles of guanfacine
extended release (GXR) and methylphenidate hydrochlo-
ride (MPH) extended release, alone and in combination.
Study Design This was an open-label, randomized, three-
period crossover, drug–drug interaction study.
Setting The study was conducted at a single clinical
research center.
Participants Thirty-eight healthy adults were randomized
in this study.
Interventions Subjects were administered single oral
doses of GXR (Intuniv; Shire Development LLC, Wayne,
PA, USA) 4 mg, MPH (Concerta; McNeil Pediatrics,
Titusville, NJ, USA) 36 mg, or GXR and MPH combined.
Main Outcome Measures Guanfacine, dexmethylpheni-
date (d-MPH), and l-methylphenidate (l-MPH) levels were
measured with blood samples collected predose and up to
72 h postdose. Safety evaluations included treatment-
emergent adverse events (TEAEs), vital signs, and elec-
trocardiograms (ECGs).
Results Thirty-five subjects completed the study. Analy-
ses of the 90 % confidence intervals (CIs) for the geometric
mean ratios of the maximum plasma concentration (Cmax)
and area under the concentration–time curve extrapolated
to infinity (AUC?) values for guanfacine and d-MPH
following administration of GXR or MPH alone or com-
bined met strict bioequivalence criteria (90 % CIs within
the interval of 0.80–1.25). Overall, combining GXR and
MPH did not alter the pharmacokinetic parameters of either
medication. Sixteen subjects (42.1 %) had at least one
TEAE. The most commonly reported TEAEs included
headache and dizziness following GXR, MPH, and GXR
and MPH combined. Two subjects had clinically signifi-
cant abnormalities in ECG results following coadminis-
tration: both events were mild and resolved the same day.
Conclusions In this short-term, open-label study of heal-
thy adults, coadministration of GXR and MPH did not result
in significant pharmacokinetic drug–drug interactions. No
unique TEAEs were observed with coadministration of
GXR and MPH compared with either treatment alone.
1 Introduction
a2-Adrenoceptor agonists such as clonidine and guanfacine
are used as adjunctive treatments to psychostimulants in
the treatment of attention-deficit/hyperactivity disorder
(ADHD) when the response to psychostimulants alone is
suboptimal [1–4]. Guanfacine extended release (GXR), a
selective a2A-adrenoceptor agonist, is approved by the US
Food and Drug Administration as monotherapy and as
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adjunctive therapy to psychostimulant medications for the
treatment of ADHD in children and adolescents aged
6–17 years [5].
The safety and efficacy of GXR in combination with
psychostimulants were demonstrated in two trials. An
open-label, 9-week study of 75 children and adolescents
with ADHD who had operationally defined suboptimal
responses to a psychostimulant found that the addition of
GXR did not result in unique adverse events (AEs) com-
pared with those reported historically with either treatment
alone, and was associated with significant improvements in
ADHD symptoms [4]. In addition, a large, multicenter,
double-blind, randomized, placebo-controlled study of
GXR as adjunctive therapy to psychostimulants in children
and adolescents aged 6–17 years with ADHD who exhib-
ited suboptimal responses to psychostimulants alone con-
firmed the results of the earlier open-label investigation and
provided further support for the effectiveness of GXR as an
adjunctive therapy to psychostimulants in this age group
[6]. Since methylphenidate hydrochloride (MPH) is con-
sidered among first-line treatments for ADHD because of
its established efficacy and safety profile [7], the potential
for pharmacokinetic drug–drug interactions between GXR
and MPH requires thorough investigation.
Although guanfacine is known to be metabolized by the
cytochrome p450 (CYP) 3A4 pathway [5], MPH is pri-
marily metabolized by de-esterification [8]. Even though
MPH is not metabolized by the CYP system and is neither
an inducer nor an inhibitor of the system [8, 9], it is
important to study the pharmacokinetics of GXR in com-
bination with MPH to confirm the lack of metabolic
interactions between these two therapies.
Although data on the pharmacokinetics of GXR used in
combination with MPH are limited, the pharmacokinetic
profiles of GXR or MPH alone have been well character-
ized [5, 10]. GXR is readily absorbed and is approximately
70 % bound to plasma proteins, independent of the drug
concentration [5]. Oral administration of single doses of
GXR in adults leads to a maximum guanfacine plasma
concentration (Cmax) in approximately 5 h [5, 11]. A sin-
gle-dose pharmacokinetic study of GXR in healthy adults
demonstrated that the single-dose pharmacokinetic
parameters of GXR 1-, 2-, and 4-mg tablets were statisti-
cally linear, with the Cmax, area under the plasma con-
centration–time curve (AUC) to the last measurable
concentration at time t (AUCt), and AUC extrapolated to
infinity (AUC?) for guanfacine increasing with dose [11].
MPH is also readily absorbed, with MPH mean concen-
trations initially plateauing at 1–4 h and ascending to
maximum plasma concentrations between 6–10 h after
administration [10, 12].
The safety profiles of both GXR and MPH alone have
also been examined in previous studies. The most common
treatment-emergent AEs (TEAEs) reported in the short-
term pivotal studies of GXR included somnolence, fatigue,
upper abdominal pain, and sedation [13, 14]. The most
common adverse reactions reported in clinical trials of
MPH included upper abdominal pain, vomiting, dizziness,
and insomnia [10]. The effects of these medications on
cardiovascular parameters have also been examined. In
subjects who received GXR in clinical trials, systolic blood
pressure (SBP), diastolic blood pressure (DBP), and pulse
rate decreased as actual doses increased, and they then
returned toward baseline as doses stabilized and were
tapered down [13–15]. These changes were expected, given
that immediate-release guanfacine was initially used as an
antihypertensive agent. In contrast, increases in SBP, DBP,
and pulse rate are often reported with MPH treatment [16,
17]. Consequently, there is a need to investigate the impact
of coadministration of GXR and MPH on these parameters
as well as the overall safety of this combination.
The primary purpose of the present study (ClinicalTri-
als.gov identifier: NCT00901576) was to evaluate the
pharmacokinetic profiles of GXR and MPH, alone and in
combination, in healthy adults. Evaluating the safety of
GXR, MPH, and coadministration of both drugs was a
secondary objective of this study.
2 Materials and Methods
This open-label, randomized, single-center, three-period
crossover, drug–drug interaction study was conducted from
18 May to 6 July 2009. Healthy adults were randomized to
receive single doses of GXR (Intuniv; Shire Development
LLC, Wayne, PA, USA) 4 mg, MPH extended release
(Concerta; McNeil Pediatrics, Titusville, NJ, USA) 36 mg,
and the combination of GXR 4 mg and MPH 36 mg. Insti-
tutional review board approval was received to conduct the
study, and informed consent was provided by all subjects.
The study was conducted in accordance with current appli-
cable regulations, International Conference on Harmonisa-
tion (ICH) Good Clinical Practice (GCP) Guideline E6, local
ethical and legal requirements, and the principles of the 18th
World Medical Assembly and amendments.
2.1 Subjects
The study subjects were healthy volunteers aged
18–45 years who exhibited no significant or relevant
abnormalities in medical history, physical examination,
vital signs, or laboratory evaluation that were reasonably
likely to interfere with the subject’s participation in or
ability to complete the study. Normal or clinically insig-
nificant electrocardiogram (ECG) findings were also
required for inclusion in the study.
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The study exclusion criteria included current or recur-
rent disease (such as cardiovascular, renal, liver, or gas-
trointestinal diseases, malignancy, or other conditions) that
could affect clinical or laboratory assessments or the
action, absorption, or disposition of the investigational
agents. Cardiac conditions, including a history of hyper-
tension or a known family history of sudden cardiac death
or ventricular arrhythmia, were also exclusionary. Other
exclusion criteria included current use of any medication
(with the exception of hormone replacement therapy or
hormonal contraceptives), use of tobacco in any form,
routine consumption of more than 2 units of caffeine per
day, or the presence of a medical or psychiatric disorder
that may have required treatment or made the subject
unlikely to comply with the study’s requirements or com-
plete the study.
2.2 Study Design
The study subjects were randomly assigned to one of six
administration sequences, each consisting of three treatment
periods separated by a washout period of at least 7 days in
duration. The subjects were allocated a 4-digit randomiza-
tion number, starting at 1001, immediately prior to the
predose pharmacokinetic blood draw after eligibility was
determined. At least six subjects were to be randomized to
each of the six possible treatment sequences (1: GXR, MPH,
GXR ? MPH; 2: GXR, GXR ? MPH, MPH; 3: MPH,
GXR, GXR ? MPH; 4: MPH, GXR ? MPH, GXR; 5:
GXR ? MPH, GXR, MPH; 6: GXR ? MPH, MPH, GXR).
The study medication was administered at a clinical
research center that was supervised by clinical staff. The
subjects were required to fast for approximately 10 h prior
to the administration of each dose of study medication. All
study medication was given with water in the morning. A
moderate-fat lunch was provided 4 h after dose adminis-
tration. The subjects were confined at the center during
each treatment period and remained there until all dis-
charge procedures were completed, approximately 72 h
after the subjects received the treatment.
2.3 Pharmacokinetic and Safety Assessments
Vital signs were monitored, blood samples collected, and
ECG data obtained before administration of the study
medication for each treatment period. Guanfacine, dexm-
ethylphenidate (d-MPH), and l-methylphenidate (l-MPH)
levels were measured in plasma produced from blood
samples collected predose and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0,
6.0, 8.0, 12, 24, 30, 48, and 72 h postdose. Immediately
after blood collection, the blood samples were kept on ice
until they were centrifuged, within 30 min following the
blood draw.
Plasma concentrations of guanfacine, d-MPH, and
l-MPH were measured using liquid chromatography with
tandem mass spectrometry (LC–MS/MS) detection meth-
ods that were validated for the quantitation of guanfacine,
d-MPH, and l-MPH in human K3-EDTA plasma. The
method utilized a liquid-liquid extraction procedure prior
to LC–MS/MS analysis. The stable isotope-labeled com-
pounds guanfacine (13C15N3) and MPH-D9 were used as
the internal standards for guanfacine and d/l-MPH,
respectively.
For guanfacine, the LC–MS/MS analysis was carried out
with a Sciex 4000 mass spectrometer coupled with a
Shimadzu liquid chromatography (LC) pump (model
LC-10AT) and Perkin-Elmer 200 series autosampler. The
chromatographic separation was achieved on a XBridge
phenyl, 3.5 lm, 4.60 9 50 mm LC column, with a mobile
phase. The mass spectrometer was operated in positive
electrospray ionization mode, and the resolution settings
used were unit for Q1 and low for Q3. The multiple
reaction monitoring (MRM) transition was m/z 246 ? 60
for guanfacine, and the MRM transition was m/z
250 ? 159 for the internal standard, guanfacine (13C15N3).
For d/l-MPH, the LC–MS/MS analysis was carried out
with a Sciex 5000 mass spectrometer coupled with a
Shimadzu LC pump (model LC-10AT) and a Perkin-Elmer
200 series autosampler. The chromatographic separation
was achieved on a ChiralPak AD-H, 4.60 9 150 mm,
5 lm LC–MS column, with a mobile phase. The mass
spectrometer was operated in positive mode, and the res-
olution setting used was unit for both Q1 and Q3. The
MRM transition was m/z 234 ? 84 for MPH, and the
MRM transition was m/z 243 ? 93 for the internal stan-
dard, MPH-D9.
The assay ranges were from 0.05 to 50 ng/mL for
guanfacine analysis, based on a plasma sample volume of
200 lL, and from 0.25 to 100 ng/mL for d-MPH and
l-MPH analysis, based on a plasma sample volume of
100 lL.
Safety was evaluated by collecting data on reported
AEs, physical examination findings, vital signs, and
12-lead ECGs. At the end of each treatment period, bio-
chemical and hematologic assessments were performed
and urinalysis was conducted. Staff contacted subjects
7 days after the last dose of the last investigational agent to
collect data on new-onset AEs and other treatment-related
concerns.
2.4 Statistical Methods
The primary analysis was the pharmacokinetic analysis
performed using data from the pharmacokinetic population.
This population consisted of all subjects who received at
least one dose of study medication, had at least one
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postdose safety assessment, and had evaluable concentra-
tion–time profiles for guanfacine, d-MPH, or l-MPH.
Pharmacokinetic parameters were determined from the
plasma concentration–time data by noncompartmental
analysis and included Cmax, time to Cmax (tmax), AUCt,
AUC?, apparent elimination half-life (t), apparent oral-
dose clearance (CL/F), and apparent volume of distribution
during the terminal phase after oral administration (Vkz/F).
CL/F and Vkz/F were corrected for bodyweight.
Summary statistics, including the numbers of observations,
means, standard deviations (SDs), medians, maximums, min-
imums, and geometric means, were determined for all phar-
macokinetic parameters for all treatment regimens.
The means of the log-transformed pharmacokinetic
parameters were compared among (between) treatments,
using an analysis of variance (ANOVA) with sequence, per-
iod, and treatment as fixed effects, and subject nested within
sequence as a random effect for a crossover study design. To
estimate the magnitude of the treatment differences in Cmax
and AUC?, the geometric mean ratio (GMR, defined as the
least squares mean difference in the log-transformed param-
eters back-transformed to the original scale) and their 90 %
confidence intervals (CIs) were also calculated.
The hypothesis of a drug interaction of GXR and MPH
would be rejected if either of the following were to fall
within the interval of 0.80–1.25: (i) the 90 % CIs of the
GMR of guanfacine following GXR alone to guanfacine
following GXR in combination with MPH; or (ii) the 90 %
CIs of the GMR of d-MPH following MPH alone to
d-MPH following MPH in combination with GXR. If the
CIs were not entirely contained within the interval of
0.80–1.25, then the clinical significance of such mean ratio
estimates and CIs would be interpreted within the context
of the therapeutic index.
The available within-subject estimates of the SDs of the
log-transformed parameters AUC? (SD = 0.26) and Cmax
(SD = 0.31) for GXR were pooled from previous studies of
GXR. Data from the ‘Summary Basis of Approvable/
Approval’ letter for MPH indicated that the intrasubject
coefficient of variation for MPH was 9.6 %, based on AUC?
(approximates to a within-subject SD of 9.5 for log-trans-
formed AUC?). A previous study of MPH reported a within-
subject SD of Cmax and AUC? of 0.18 [18]. To demonstrate
equivalence, allowing for a 5 % difference in true means, if
the true within-subject SD was 0.25 (based on the higher of
the AUCs between GXR and MPH), 36 subjects (six per
sequence) were required to achieve 90 % power.
3 Results
Thirty-eight subjects were randomized, and 35 (92.1 %)
completed the study. No subject withdrew because of an
AE, and there were no substantial differences among
treatment sequences in the reasons for study discontinua-
tion. Three subjects did not complete the study: two
withdrew from the study and one was withdrawn by the
study investigator before she received GXR and MPH in
combination, because she had tolerated GXR and MPH
poorly when each was administered alone. Demographics
and baseline characteristics are reported in Table 1.
3.1 Pharmacokinetic Results
A summary of pharmacokinetic parameters of guanfacine
and d-MPH following administration of GXR alone, MPH
alone, and GXR and MPH in combination is presented in
Table 2.
The mean plasma guanfacine concentrations following
administration of GXR alone and in combination with
MPH are shown in Fig. 1. No noteworthy differences
in guanfacine Cmax, AUC?, and bodyweight-normalized
Table 1 Summary of demographic and baseline characteristics of
the study population (N = 38)a
Characteristic Value
Age (years)
Mean [SD] 30.8 [6.28]
Median 30.5





Mean [SD] 77.7 [10.40]
Median 76.3
Minimum, maximum 56, 100
Height (cm)
Mean [SD] 173.8 [9.43]
Median 174.0
Minimum, maximum 151, 194
Body mass index (kg/m2)
Mean [SD] 25.6 [2.26]
Median 25.2
Minimum, maximum 22, 30
Ethnicity (n [%])
Hispanic or Latino 15 [39.5]
Not Hispanic or Latino 23 [60.5]
Race (n [%])
White 19 [50.0]
Black or African American 19 [50.0]
SD standard deviation
a Percentages are based on the number of subjects in the safety
population and in each randomized treatment sequence
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CL/F and Vkz/F were noted after administration of GXR
alone or in combination with MPH. The 90 % CIs of the
GMRs for Cmax and AUC? for guanfacine following GXR
alone or in combination with MPH met strict bioequiva-
lence criteria requiring 90 % CIs to fall within the interval
of 0.80–1.25 (Cmax GMR 1.065, 90 % CI 0.945–1.200;
AUC? GMR 1.109, 90 % CI 0.997–1.235), indicating that
GXR alone and GXR in combination with MPH met the
criteria for bioequivalence.
The mean plasma concentrations of d-MPH follow-
ing administration of MPH alone and in combination
with GXR are shown in Fig. 2. Maximum plasma
concentrations of d-MPH were observed at a median of 6 h
when MPH was administered alone and at 8 h when MPH
was administered in combination with GXR (Table 2).
Cmax, AUC?, and bodyweight-normalized CL/F and Vkz/F
results for d-MPH were similar after administration of
MPH alone and in combination with GXR. In addition, no
noteworthy differences in l-MPH concentrations following
administration of MPH alone or in combination with GXR
were noted (Table 2). Moreover, the 90 % CIs of the
GMRs for Cmax and AUC? with d-MPH following MPH
alone or in combination with GXR met strict bioequiva-
lence criteria requiring 90 % CIs to fall within the interval
Table 2 Pharmacokinetic parameters of guanfacine, dexmethylphenidate (d-MPH), and l-methylphenidate (l-MPH)
Parameter Cmax (ng/mL) tmax (h) AUC? (ngh/mL) t (h) CL/F (L/h/kg) Vkz/F (L/kg)
Summary of guanfacine pharmacokinetic parameters, pharmacokinetic population
GXR alone
N 37 37 33 33 33 33
Mean [SD] 2.6 [0.9] 8.1 [8.1] 96.5 [37.3] 20.4 [7.9] 0.6 [0.2] 16.9 [5.8]
Median 2.4 6 86.6 17.3 0.6 16.6
Minimum, maximum 1.3, 4.9 2, 48 38.9, 175.2 11, 40.4 0.3, 1.3 6.3, 30.8
GXR ? MPH
N 36 36 34 34 34 34
Mean [SD] 2.7 [0.9] 8.7 [6.3] 106.7 [39.9] 22.7 [10.6] 0.6 [0.2] 16.7 [6.2]
Median 2.6 6 103.7 19.2 0.5 15.1
Minimum, maximum 1.3, 4.9 3, 30 38.5, 218.4 12.7, 55.2 0.25, 1.3 8.9, 34.7
Summary of d-MPH pharmacokinetic parameters, pharmacokinetic population
MPH alone
N 38 38 32 32 32 32
Mean [SD] 9.9 [2.8] 6.9 [1] 102.8 [34.6] 3.9 [0.7] 5.1 [1.7] 28.8 [11.6]
Median 10.1 6 100.2 3.8 4.9 24.1
Minimum, maximum 5.1, 16.0 6, 8.1 50.2, 216.3 2.9, 5.7 2.2, 8.7 15.9, 71.3
GXR ? MPH
N 37 37 32 32 32 32
Mean [SD] 9.5 [2.9] 7.4 [1.3] 100.5 [33] 4.1 [0.6] 5.0 [1.4] 28.6 [7.1]
Median 8.8 8 94.9 4 5.2 28.5
Minimum, maximum 5.4, 18.2 6, 12 57.6, 215.7 3.1, 5.3 2.2, 7.2 15.2, 40.2
Summary of l-MPH pharmacokinetic parameters, pharmacokinetic population
MPH alone
N 38 13 38 0 0 0
Mean [SD] 0.2 [0.3] 6.5 [0.9] 0.5 [0.9] – – –
Median 0 6 0 – – –
Minimum, maximum 0, 0.9 6, 8 0, 4.2 – – –
GXR ? MPH
N 37 9 37 0 0 0
Mean [SD] 0.2 [0.5] 6.4 [0.9] 0.7 [2.0] – – –
Median 0 6 0 – – –
Minimum, maximum 0, 2.6 6, 8 0, 11 – – –
AUC? area under the plasma concentration–time curve extrapolated to infinity, CL/F apparent oral-dose clearance, Cmax maximum plasma
concentration, GXR guanfacine extended release, MPH methylphenidate hydrochloride, SD standard deviation, t apparent elimination half-life,
tmax time to Cmax, Vkz/F apparent volume of distribution during the terminal phase after oral administration
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of 0.80–1.25 (Cmax GMR 0.957, 90 % CI 0.907–1.01;
AUC? GMR 1.001, 90 % CI 0.958–1.046), demonstrating
the bioequivalence of MPH alone and with GXR.
3.2 Safety Results
Sixteen subjects (42.1 %) had at least one TEAE. The
most commonly reported TEAEs included headache
(5.4, 10.5, and 8.1 % following GXR, MPH, and GXR
and MPH combined, respectively), dizziness (2.7, 5.3, and
2.7 %, respectively), and postural dizziness (8.1, 0.0 and
0.0 %, respectively). The TEAEs observed were consis-
tent with the known effects of GXR and MPH adminis-
tered alone.
One event (orthostatic syncope) was considered serious
but was mild in severity and did not lead to study dis-
continuation. The subject was a 22-year-old male who had
no relevant history, no history of syncope, and no recent
illness. The event occurred 2 h after he received his first
treatment, which was a single oral dose of GXR 4 mg
alone. The event lasted less than 1 minute, and the subject
recovered spontaneously and completed the study.
No subject had a severe AE or an AE leading to with-
drawal. The majority of TEAEs were mild, and no differ-
ences in the types, incidences, or severity of TEAEs were
reported across treatments. No clinically meaningful dif-
ferences in biochemistry, hematology, or urinalysis results
across treatment groups were noted.
The effects of monotherapy with GXR or MPH on vital
signs, including SBP, DBP, and supine pulse rate, were as
expected. Figure 3 shows the mean supine pulse rates over
the course of 12 h following administration of GXR, MPH,
and GXR and MPH. Following administration of GXR,
there was a modest decrease in the mean pulse rate, which
started returning to baseline levels 6 h postdose. In con-
trast, a modest increase in the mean supine pulse rate was
seen with MPH.
Changes in supine SBP (Fig. 4a) and DBP (Fig. 4b)
were also noted after administration of GXR and MPH
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Fig. 1 Mean plasma
guanfacine concentrations over
time following administration of
guanfacine extended release
(GXR) alone and in
combination with
methylphenidate hydrochloride
(MPH). A time shift has been
applied to the figure; values
have been slightly staggered on
the x-axis for clarity, as some
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(MPH) alone and in
combination with guanfacine
extended release (GXR). A time
shift has been applied to the
figure; values have been slightly
staggered on the x-axis for
clarity, as some values were
similar between the two
treatment regimens
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with GXR, and small increases in BP were reported with
MPH.
As shown in Figs. 3 and 4, the results for GXR and
MPH combined suggested a potential offsetting effect on
pulse rate (Fig. 3) and BP (Fig. 4) with coadministration,
compared with the effects observed when each medication
was administered alone. Postural orthostatic changes in
pulse rate and BP after coadministration of GXR and MPH
were highly variable. There did not appear to be clinically
important postural orthostatic changes in pulse rate or BP
following coadministration of GXR and MPH compared
with GXR alone.
Two subjects had potentially clinically significant
abnormalities in ECG results based upon prespecified
parameters (asymptomatic supraventricular extrasystoles




























Fig. 3 Mean (±standard
deviation) supine pulse rate over
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Fig. 4 a Mean [±standard
deviation (SD)] supine systolic
blood pressure (SBP) and
b mean (±SD) supine diastolic
blood pressure (DBP) over
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occurred 2 h after coadministration of GXR and MPH,
were mild in severity, and resolved the same day. These
abnormalities were determined not to be clinically mean-
ingful ECG changes; overall, ECG results were consistent
with the known effects of these compounds.
4 Discussion
In clinical practice, a2-adrenoceptor agonists such as GXR
have been coadministered with psychostimulants such as
MPH to treat ADHD, and GXR is now indicated as
adjunctive therapy to psychostimulant medications for the
treatment of ADHD [2, 19]. Although guanfacine is known
to be metabolized by the CYP3A4 system [5], and MPH is
neither an inducer nor an inhibitor of that system, it was
considered prudent to evaluate the pharmacokinetics of this
combination.
In this study of healthy adults, no pharmacokinetic drug
interactions were observed with coadministration of GXR
and MPH. No noteworthy differences in pharmacokinetic
parameters were observed with GXR and MPH in combi-
nation compared with either medication alone. In fact,
analyses of the 90 % CIs of the GMRs for Cmax and AUC?
of guanfacine alone or in combination with MPH, or MPH
alone or in combination with GXR, met strict bioequiva-
lence criteria (90 % CIs within the interval of 0.80–1.25).
The TEAEs reported in this study were expected and
consistent with those observed historically with psycho-
stimulants administered alone or with GXR [5, 10, 13, 14,
20]. No differences in the type, incidence, or severity of
TEAEs among treatment groups were observed, and no
subject discontinued treatment because of a TEAE.
No clinically meaningful changes in ECG results, lab-
oratory parameters, or physical examination findings were
noted during the study. Modest changes in BP and supine
pulse rate were seen with GXR and MPH treatment alone
and were expected. When GXR and MPH were coadmin-
istered as single doses, data from this study indicated a
potential offsetting effect on pulse rate and BP, compared
with the effects typically observed with either treatment
alone. Because this study evaluated the impact of only a
single dose of GXR and MPH, alone and in combination, it
is unknown if this effect would continue with longer-term
therapy.
This study had several limitations. It was a small, short-
term, open-label study that only included healthy adult men
and women. This population is not representative of the
range of patients who are treated with GXR coadministered
with a stimulant. Additionally, patients with ADHD have a
higher prevalence of comorbid disorders, such as depres-
sion, anxiety, and oppositional disorder, compared with
control subjects, and subjects with those disorders were
excluded [21]. As this was a single-dose study, rather than
a multiple-dose study, the effects seen in the study may not
be representative of those seen at steady state. Because of
these limitations, the findings of this study may not be
readily extrapolated to the therapeutic setting. Moreover,
because of the short-term nature of the study, the impli-
cations of the results for long-term management of ADHD
with a combination of GXR and MPH are also unknown.
This study was not designed to robustly assess the car-
diovascular effects of either GXR or MPH alone or in
combination. In fact, the study excluded subjects with
comorbidities that might contribute to cardiac AEs and
subjects with medical or psychiatric disorders. Therefore, it
is important to be cautious when generalizing from the
results of this study.
5 Conclusions
In this short-term, open-label study of healthy adults, coad-
ministration of GXR and MPH did not result in significant
pharmacokinetic drug–drug interactions. In addition, no
unique TEAEs were observed with coadministration of GXR
and MPH compared with either treatment alone.
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